With RNAi across the hemophilia
October 23, 2015

RNA interference (RNAi) may be used as a therapeutic for the bleeding disorder hemophilia. Specifically, artificially-generated, epigenetically-activated RNA molecules such as microRNAs can be used to inhibit gene expression through post-translational gene silencing. Researchers from France and the USA recently treated hemophiliac mice and macaques with a successful RNAi compound (ALN-AT3), which supresses the production of the anti-clotting substance antithrombin. Currently this therapeutic is being investigated in phase 1 clinical trials in individuals with hemophilia A or B.

Source: http://www.newsletter-epigenetik.de/

Read more


  • IMB Conference on "Epigenetics of Ageing - Responses to Adversity across Scales" 2022
    Rheinland-Pfalz, Germany
    Jun 28-Jul 1, 2022
  • CNET 2022
    Gif-Sur-Yvette, France
    Jul 4-Jul 6, 2022
 See all events


 See all news

The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics